Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.71 |
| ▸ | GAA | P10253 | 2/20 | 0.71 |
| ▸ | MPO | P05164 | 1/20 | 0.71 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.71 |
| ▸ | NPC1 | O15118 | 5/20 | 0.65 |
| ▸ | RAB9A | P51151 | 4/20 | 0.65 |
| ▸ | CRHBP | P24387 | 1/20 | 0.65 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 6/20 | 0.63 |
| ▸ | HPGD | P15428 | 5/20 | 0.63 |
| ▸ | HTT | P42858 | 4/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.63 |
| ▸ | TP53 | P04637 | 3/20 | 0.63 |
| ▸ | MEN1 | O00255 | 3/20 | 0.63 |
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19032011 | 0.89 | NPC1 (0.70) | KDM4ESMN1; SMN2GAAMPOHIF1A | |
| Salicylamide SCHEMBL18591525 | 0.89 | KDM4E (0.76) | KDM4ESMN1; SMN2GAAMPOHIF1A | |
| SCHEMBL10904872 | 0.89 | KDM4E (0.63) | KDM4ESMN1; SMN2GAAMPOHIF1A | |
| SCHEMBL6994934 | 0.89 | KDM4E (0.63) | KDM4ESMN1; SMN2GAAMPOHIF1A | |
| Salacetamide SCHEMBL25410 | 0.87 | KDM4E (0.61) | KDM4ESMN1; SMN2GAAMPOHIF1A | |
| SCHEMBL77381 | 0.85 | CA1 (0.77) | KDM4ESMN1; SMN2GAAMPOHIF1A | |
| SCHEMBL23875051 | 0.83 | CA1 (0.58) | KDM4ESMN1; SMN2GAAMPOHIF1A | |
| SCHEMBL16358867 | 0.83 | CA1 (0.73) | KDM4ESMN1; SMN2GAAMPOHIF1A | |
| SCHEMBL15372514 | 0.83 | KMT2A (0.71) | KDM4ESMN1; SMN2GAAMPOHIF1A | |
| SCHEMBL12829081 | 0.83 | NPC1 (0.76) | KDM4ESMN1; SMN2GAAMPOHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2964659-B1 | PROCESS FOR THE PREPARATION OF DEFERASIROX | BIOCON LTD (IN) | 2017-08-09 | — | — | EP | claimed |
| US-20160024025-A1 | PROCESS FOR THE PREPARATION OF DEFERASIROX | BIOCON LIMITED (IN) | 2016-01-28 | — | — | US | claimed |
| EP-2964659-A2 | PROCESS FOR THE PREPARATION OF DEFERASIROX | Biocon Limited (IN) | 2016-01-13 | — | — | EP | claimed |
| WO-2014136062-A2 | PROCESS FOR THE PREPARATION OF DEFERASIROX | BIOCON LIMITED (IN) | 2014-09-12 | — | — | WO | claimed |
| WO-2011021218-A2 | PROCESS FOR THE PREPARATION OF 4-[3,5-BIS(2-HYDROXYPHENYL)-1H-1,2,4-TRIAZOL-1-YL]-BENZOIC ACID AND ITS AMINE SALTS | MSN LABORATORIES LIMITED (IN) | 2011-02-24 | — | — | WO | claimed |
| EP-2964659-B1 | PROCESS FOR THE PREPARATION OF DEFERASIROX | BIOCON LTD (IN) | 2017-08-09 | — | — | EP | disclosed |
| EP-2964659-B1 | PROCESS FOR THE PREPARATION OF DEFERASIROX | BIOCON LTD (IN) | 2017-08-09 | — | — | EP | disclosed |
| US-9593086-B2 | Process for the preparation of deferasirox | BIOCON LIMITED (IN) | 2017-03-14 | — | — | US | disclosed |
| US-9593086-B2 | Process for the preparation of deferasirox | BIOCON LIMITED (IN) | 2017-03-14 | — | — | US | disclosed |
| US-9593086-B2 | Process for the preparation of deferasirox | BIOCON LIMITED (IN) | 2017-03-14 | — | — | US | disclosed |
| US-20160024025-A1 | PROCESS FOR THE PREPARATION OF DEFERASIROX | BIOCON LIMITED (IN) | 2016-01-28 | — | — | US | disclosed |
| US-20160024025-A1 | PROCESS FOR THE PREPARATION OF DEFERASIROX | BIOCON LIMITED (IN) | 2016-01-28 | — | — | US | disclosed |
| WO-2011070560-A1 | PROCESSES FOR THE PREPARATION OF DEFERASIROX, AND DEFERASIROX POLYMORPHS | MAPI PHARMA HK LIMITED (CN) | 2011-06-16 | — | — | WO | disclosed |
| WO-2011070560-A1 | PROCESSES FOR THE PREPARATION OF DEFERASIROX, AND DEFERASIROX POLYMORPHS | MAPI PHARMA HK LIMITED (CN) | 2011-06-16 | — | — | WO | disclosed |
| WO-2011021218-A2 | PROCESS FOR THE PREPARATION OF 4-[3,5-BIS(2-HYDROXYPHENYL)-1H-1,2,4-TRIAZOL-1-YL]-BENZOIC ACID AND ITS AMINE SALTS | MSN LABORATORIES LIMITED (IN) | 2011-02-24 | — | — | WO | disclosed |
| WO-2011021218-A2 | PROCESS FOR THE PREPARATION OF 4-[3,5-BIS(2-HYDROXYPHENYL)-1H-1,2,4-TRIAZOL-1-YL]-BENZOIC ACID AND ITS AMINE SALTS | MSN LABORATORIES LIMITED (IN) | 2011-02-24 | — | — | WO | disclosed |
| US-20110034702-A1 | METHOD FOR PREPARING 4-[3,5-BIS(2-HYDROXYPHENYL)-[1,2,4]TRIAZOL-1-YL]-BENZOIC ACID | FARMAK, A.S. (CZ) | 2011-02-10 | — | — | US | disclosed |
| US-20110034702-A1 | METHOD FOR PREPARING 4-[3,5-BIS(2-HYDROXYPHENYL)-[1,2,4]TRIAZOL-1-YL]-BENZOIC ACID | FARMAK, A.S. (CZ) | 2011-02-10 | — | — | US | disclosed |
| WO-2009094956-A1 | A METHOD FOR PREPARING 4-[3,5-BIS(2-HYDROXYPHENYL)-[1,2,4]TRIAZOL-1-YL]-BENZOIC ACID | FARMAK, A.S. (CZ) | 2009-08-06 | — | — | WO | disclosed |
| WO-2001030746-A1 | METHOD FOR PREPARING A HYDROXYBENZONITRILE | RHODIA CHIMIE (FR) | 2001-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034702-A1 | METHOD FOR PREPARING 4-[3,5-BIS(2-HYDROXYPHENYL)-[1,2,4]TRIAZOL-1-YL]-BENZOIC ACID | HAO2, HPD, HAO1 | KDM4E 1883/4885SMN1; SMN2 3896/4885GAA 673/4885 |
| US-20160024025-A1 | PROCESS FOR THE PREPARATION OF DEFERASIROX | PRPF8, SF3A2, FECH | KDM4E 1093/4885SMN1; SMN2 1231/4885GAA 814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.